Background: The aim of this phase II study was to assess the activity of panitumumab in combination with oxaliplatin, 5-fluorouracil, and external radiotherapy (RT) as preoperative treatment in locally advanced rectal cancer patients.
introduction
In locally advanced rectal cancer (LARC) patients, neoadjuvant preoperative chemoradiation has been shown to increase the pathological complete response (pCR) and locoregional control but has not demonstrated an improvement in overall survival (OS) [1] [2] [3] . Currently, preoperative 5-fluorouracil and radiotherapy (RT) followed by total mesorectal excision (TME) is standard treatment in this patient setting. Two phase III trials, ACCORD 12/0405 Prodige 2 and Studio Terapia Adiuvante Retto (STAR)-01, added oxaliplatin in preoperative chemotherapy without obtaining a statistically significant increase in pCR [4, 5] .
Epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that is a member of the tyrosine kinase growth factor receptor superfamily. EGFR represents an important therapeutic target in cancer, and regulates cellular growth, survival, proliferation, and differentiation. In rectal cancer, EGFR is overexpressed in 50%-70% of primary tumors [6] . In patients with rectal cancer after preoperative chemo-RT, EGFR overexpression is related to a decrease in the pathologically documented response (pathological response), disease-free survival (DFS), and OS [7, 8] .
The pCR rate has been considered a prognostic factor for LARC patients undergoing neoadiuvant chemo-RT, and pCR has been associated with favorable DFS and OS [9, 10] . Monoclonal antibodies against EGFR (cetuximab, panitumumab) have shown activity in patients with chemorefractory metastatic colorectal cancer and as first-line therapy in metastatic colorectal cancer [11] [12] [13] [14] [15] . In two phase III trials, panitumumab (VectibixÒ; Amgen Inc, Thousand Oaks, CA), a fully human monoclonal immunoglobulin G2 antibody, added to first-(FOLFOX) and second-line (FOLFIRI) chemotherapy significantly increased the response rate in metastatic colorectal cancer patients. Radiation increases EGFR expression in cancer cells, and the EGFR signaling blockade sensitizes the cells to the effects of radiation [16, 17] . In a phase III study with cetuximab and concurrent RT in patients with locally advanced head and neck cancer, locoregional control and OS significantly improved [18, 19] . Various mechanisms for this cetuximab synergistic activity have been proposed, including the inhibition of repopulation during RT fractions [20, 21] .
In the present phase II study, the efficacy of the addition of panitumumab to 5-fluorouracil and oxaliplatin chemotherapy with concurrent external RT was investigated as neoadjuvant treatment in LARC high-risk patients.
patients and methods

study design
We conducted a multicenter phase II study approved by the local ethical committee, registered with the health authorities (EUDRACT 2007-001533-34). The primary end point was pCR rate. Secondary end points were median survival time (OS), time to DFS, surgery sphincter preservation, and toxicity. The biological and metabolic markers are investigated in a collateral study (Figure 1 ).
patient eligibility criteria
The eligibility criteria included the following: histologically proven rectal adenocarcinoma of the mid-low rectum (within 12 cm from the anal verge), Karnofsky performance status ‡70%, stage cT3N+M0 and cT4N2/+ M0 [N+ stage, three or more lymph nodes of diameter ‡0.5 cm measured by endorectal ultrasound or one or more lymph nodes of diameter ‡1 cm measured by magnetic resonance (MR)], no previous treatment with chemotherapy or radiation therapy, neutrophil count ‡1500/ll, platelet count ‡100 000/ll, hemoglobin level ‡9.0 g/dl, serum creatinine level £1.5 · upper limit of normal (ULN), alanine aminotransferase and aspartate aminotransferase levels £2.5 · ULN, total bilirubin level £1.5 · ULN, and signed written informed consent.
pretreatment evaluation
The baseline evaluation included history, physical examination (including digital rectal examination), recording of concomitant medication, laboratory tests (hematology and clinical chemistry, carcinoembryonic antigen), full colonoscopy, rigid rectoscopy, biopsy, endorectal ultrasound and/or pelvic MR, and computed tomography (CT) of the thorax, abdomen, and pelvis.
panitumumab and chemo-RT treatment
Panitumumab at the dose of 6 mg/kg i.v. over 1 h was administered 2 weeks before the start of chemo-RT (day 214), and after in combination with chemo-RT every 2 weeks, for a total of three times. 5 
surgery and histopathology
Surgical treatment was planned after 7-8 weeks from the end of preoperative chemo-RT. TME was carried out according to a standardized technique. The pathological response criteria were assessed on the basis of pathological findings of the surgical specimen. The resected specimens were staged using the American Joint Committee on Cancer TNM (tumornode-metastasis) system [22] . A radical resection (R0) was defined as the removal of all macroscopic tumor tissue, no evidence of distant metastases, the absence of microscopic residual tumor, free resection margins, and lymphadenectomy extended beyond involved nodes at postoperative pathological examination. A resection was judged as nonradical when microscopic (R1 £1 mm) or macroscopic (R2) residual tumor was found. Furthermore, each specimen was classified using a tumor regression grade proposed by Dworak et al. [23] . Tumor downstaging was determined by comparing the pathological stage with the baseline clinical TNM stage; pCR was defined as the absence of viable tumor cells in the primary tumor and lymph nodes (ypT0N0).
postoperative chemotherapy
Postoperative chemotherapy with FOLFOX4 regimen in combination with panitumumab for eight cycles was planned after surgical treatment after a minimum of four weeks and a maximum of six weeks.
statistical analysis
The primary end point was the pCR rate after neoadjuvant treatment. A pCR rate of 25% was considered to qualify the experimental treatment as promising for additional study. Using Fleming's [24] single-stage design, adapted for binomial distribution according to A'Hearn [25] , a total recruitment of 53 subjects and a critical value of 19 responses have defined a study with 85% power to reject the null hypothesis that the pCR is £24% using a one-sided 10% significance level when the true pCR is ‡40%.
biological and positron emission tomography studies
Mutational status analyses of KRAS, BRAF, and PIK3CA were carried out in biopsy before treatment. Genomic DNA was extracted from highly enriched paraffin-embedded tumor specimens. The status of KRAS (exon 2), BRAF (exon 15), and PIK3CA (exons 9, 20) was ascertained by PCR amplification followed by direct sequencing. Serum vascular endothelial growth factor (sVEGF), plasma VEGF (pVEGF), serum E-selectin, transforming growth factor-a (TGF-a), and epidermal growth factor (EGF) levels were determined on day 214 (baseline) and on days 1 (after panitumumab), 8 and 22 (during , and after the end of chemo-RT (before surgery). Standard uptake value (SUV1 basal, SUV2 after the first panitumumab administration, and SUV3 before surgery) was determined from the most active tumor site. FDG-PET scan was carried out following a standard procedure, as reported elsewhere, using a dedicated PET-CT tomograph (GE Discovery) [26] . The acquisition time was in a two-dimensional mode for 4 min per bed position, and the attenuation correction was carried out using a CTbased method (120 kV, 80 mA).
results patient population
From February 2007 to October 2009, 60 patients in 11 Italian centers were enrolled. All 60 patients were assessed for safety, and 57 were assessable for response. Three patients were not assessable for response as one patient died of gastrointestinal toxicity in week 5 of treatment, and two patients refused surgery. The patient characteristics are listed in Table 1 . The majority of patients were men (66.7%); their median age was 60 years (range 37-75 years) and the median Karnofsky performance status 90 (range 80-100). Median distance from the anal margin was 6 cm (range 0-12 cm). The clinical stage was cT3 in 42 of the 60 (70.0%) patients and cT4 in 18 (30.0%). The majority of patients (52/60; 86.6%) had lymph node involvement (cN+).
treatment exposure
Fifty percent of patients had at least one dose reduction, and 5.6% required a 0%-25% dose reduction of the preoperative treatment. The dose intensities of panitumumab, 5-fluorouracil, oxaliplatin, and RT are reported in Table 2 . Panitumumab dose intensity >90% was delivered in 42 of 55 (76.4%) patients. The dose of 5-fluorouracil and oxaliplatin was reduced >40% due to toxicity in 12.7% and 18.2% of patients, respectively. The full dose of planned RT was administered in 47 of 55 (85.5%) patients and >90% in 50 of 55 (90.9%) patients. Eighteen patients with T4 tumors had received the extended nodal irradiation of the external iliac.
surgical procedures and pathological responses
Data on the surgical procedures and the pathological responses are listed in Table 3 . Five patients did not undergo surgery: two patients due to disease progression (one liver metastasis, one lung metastasis) during the neoadjuvant treatment, one patient died due to gastrointestinal toxicity (diarrhea) correlated to treatment, and two patients due to refusal. Fifty-five (91.7%) patients underwent surgery and were assessable for pathological response. TME surgery was carried out in all patients. Forty-six (83.6%) patients were treated with a low anterior resection, 4 (7.3%) with a Hartmann's procedure, and 5 (9.1%) with an abdominoperineal resection. No postoperative deaths occurred. Resection (R0) at the primary tumor site was achieved in 43 of 55 (78.2%) patients. Sphincter-sparing surgery was carried out in 50 of 55 (90.9%) patients and in 7 of 16 (43.8%) patients assessed to require an abdominoperineal resection before neoadjuvant treatment. pCR (ypT0N0) rate of 21.1% (95% confidence interval 10.4% to 31.6%) was observed in 12 of 57 patients (55 resected and 2 clinical disease progression). 
safety
All 60 patients were evaluated for toxicity. Adverse events observed during the neoadjuvant treatment are listed in Table 4 . Diarrhea was the most observed toxicity, occurring in 23 (38.9%) patients, with grades 3-4. Grade 3 nausea and vomiting occurred in three (5.1%) and one (1.7%) patients, respectively. Grade 3 neutropenia was recorded in only one (1.7%) patient; no cases of grade 3-4 thrombocytopenia and anemia were observed. All grades of acne-like rash occurred in 46 patients (77.9%), and grades 3-4 were observed in 11 (18.6%). One toxic death was observed for diarrhea.
biomarker and PET studies
Mutational status of KRAS, BRAF, and PIK3CA was evaluated in 27 of 55 (49.1%) patients. KRAS mutations were detected in 4 (14.8%) of the tumors analyzed (G12A and G12D, one case each; G13D, two cases) and BRAF in 1 of 27 (3.7%) cases (V600E). No PIK3CA mutations were found. In this patient cohort, oncogenic activation of KRAS was not significantly associated with the pathological responses. Twenty-three patients enrolled in two centers were available for the biomarker evaluation (Table 5 ) and 28 patients for the FDG-PET study.
The median basal values of circulating biomarkers (at day 214) were as follows: sVEGF 465.7 pg/ml, pVEGF 114.2 pg/ml, E-selectin 35.0 ng/ml, TGF-a 33.5 pg/ml, and EGF 534.4 pg/ml. Panitumumab treatment increased the levels of TGF-a, sVEGF, and E-selectin. On day 1 after only one panitumumab administration, the sVEGF, E-selectin, and TGFa median values presented the following higher levels as compared with baseline: sVEGF 555.0 pg/ml (P = 0.027), Eselectin 50.5 ng/ml (P < 0.001), and TGF-a 68.1 pg/ml (P = 0.006) in all patients. Up-regulation of pVEGF after panitumumab administration was observed in patients with pathological downstaging (373.8 pg/ml; P = 0.01). The decrease in EGF level was observed soon after panitumumab administration (418.3 pg/ml; P = 0.82) and it reached a significant level at day 36 (339.0 pg/ml; P = 0.001). No correlations were found between EGF level modifications and the pathological response.
The median SUV1 of PET scan was 16.1 (range 6.1-26.9) and after only panitumumab administration (SUV2) it decreased to 10.2 (range 1.9-25.2; P = 0.019). SUV3 further decreased to 4.9 (range 0-17; P < 0.001). The decrease of SUV2 and SUV3 was not related to pathological downstaging.
postoperative chemotherapy
Postoperative chemotherapy with FOLFOX4 in combination with panitumumab was administered in 40 of 55 (72.7%) patients.
discussion
In LARC patients, the randomized phase III trials STAR-01 and ACCORD 12/0405 Prodige 2 showed a pCR rate of 16% 
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and 19%, respectively, using a neoadjuvant combination of fluoropyrimidine, oxaliplatin, and RT [4, 5] . The addition of anti-EGFR monoclonal antibodies to preoperative concurrent RT and chemotherapy regimens was postulated to improve pCR. The phase II trials of preoperative chemoradiation using anti-EGFR monoclonal antibodies are summarized in Table 6 . In the Italian phase II study, cetuximab and a continuous infusion of 5-fluorouracil 225 mg/m 2 /day concomitantly with RT (50.4 Gy in 25-28 fractions) were administered in 40 patients, with pCR in 3 patients (8%) [27] . In the Belgian phase I/II study, 40 patients were treated with cetuximab in combination with capecitabine 650 and 825 mg/m 2 twice daily (dose recommended) continuously for the duration of RT (45 Gy in 25 fractions), with pCR in 2 patients (5%) [28] . No pCR was obtained in 28 patients treated with cetuximab in combination with capecitabine 825 mg/m 2 twice daily on RT days (45 Gy in 25 fractions) [29] . Velenik et al. [30] [33] .
In the StarPan (STAR-02) Study, the primary end point is not reached, with a pCR rate of 21.1%. However, in this trial, the addition of panitumumab to 5-fluorouracil-oxaliplatin chemo-RT showed a high pCR rate as compared with the results of the phase II studies based on cetuximabfluoropyrimidine combination with or without oxaliplatin. These data should be interpreted as hypothesis-generating in regard to the chemo-RT schedules.
The biological mechanisms for the disappointing results of cetuximab in combination with fluoropyrimidine-based chemo-RT in these phase II studies [27] [28] [29] [30] [31] 33] might arise from changes in tumor cell proliferation and cell cycle distribution after cetuximab administration, with cell arrest in G1 or G2/M and a failure to pass through the S phase. This hypothesis is supported by evidence in the pathological and molecular evaluation from the Belgian study that cetuximab down-regulated genes involved in proliferation (PIK3R1, CGREF1, PLAGL1), confirmed by immunohistochemistry for Ki67 [34] . Capecitabine-5-fluorouracil and oxaliplatin both produced their optimal cytotoxic and radiosensitizing effects when cells proliferate into the S/G2/M phase. Therefore, these cellular modifications could produce an antagonistic effect on fluoropyrimidine-oxaliplatin chemo-RT but would be less likely to be impacted by irinotecan.
One possible explanation for the higher pCR in StarPan Study could arise from the different chemotherapy schedules employed that could overcome the antagonistic effect of anti-EGFR monoclonal antibodies. In our study, 5-fluorouracil is administered continuously (without intervals) and oxaliplatin weekly for six times, at the full optimal dose, maintaining the synergistic and radiosensitizing effect of the two drugs [35] . These activities were lacking when 5-fluorouracil and capecitabine are administered in monotherapy (27) (28) (29) (30) or in combination with oxaliplatin with intermittent schedules [31] . In combination with irinotecan, the activity seems to be preserved only with full capecitabine dose [32, 33] .
In our StarPan Study, although the number of assessed patients was small, the presence of KRAS and BRAF mutations in the pretherapeutic biopsy was not correlated with the pathological tumor response. The significance of KRAS and BRAF mutations in patients with rectal cancer submitted to preoperative chemo-RT is not well known. In one study in 37 patients, the presence of specific KRAS mutations (codons 12, 13, and 61) was an indicator of tumor response in patients with LARC treated by preoperative 5-fluorouracil-based chemo-RT [36] . The mutation status of KRAS and BRAF in 95 LARC patients treated with 5-fluorouracil-based neoadjuvant chemo-RT was not correlated with pathological response [37] . The results of three phase II studies in patients with LARC treated with cetuximab in combination with chemo-RT did not show a significantly better response in tumor without KRAS mutations [34, 38, 39] .
In our study, the circulating levels of the EGFR ligands (TGFa, EGF) and vascular factors (sVEGF, E-selectin) were modified original article Annals of Oncology after only panitumumab administration. TGF-a, sVEGF, and E-selectin were up-regulated in almost all patients independently of response. In the preoperative treatment of rectal cancer, a similar up-regulation of circulating levels of TGF-a was observed after cetuximab administration alone [34] . The increase in angiogenetic factors is similar to that seen in a phase II study with bevacizumab in neoadjuvant chemoradiation of rectal cancer [40] . Moreover, results from our study suggest that in the responder patients, the higher EGF basal levels may up-regulate the EGFR, while the earlier circulating EGF level decrease could serve as a predictor of tumor downstaging. In our study, the FDG uptake (a measure of tumor metabolic rate) was decreased compared with the basal value by panitumumab administration alone and markedly by combination therapy. The earlier changes in the PET evaluation appear to be correlated to reduction in the tumor cell proliferation after panitumumab administration alone, and afterward, the addition of chemo-RT to panitumumab increases the cytotoxic activity. Earlier PET evaluation in this patient setting is not predictive of pathological response but may be only a marker of cellular proliferation down-regulation.
The gastrointestinal toxicity was the main toxicity of the StarPan Study. This panitumumab combination treatment was associated with very high incidence of grade 3-4 diarrhea that reached 38.9%. The rate of grade 3-4 of diarrhea in two fluoropyrimidine-oxaliplatin phase III trials was 12.6% and 15% [4, 5] , and varied from 5% to 30% in the cetuximab combination phase II studies [27] [28] [29] [30] [31] . In our study, therefore, the addition of panitumumab is likely to have been the main factor for the increase in grade 3-4 diarrhea. The specific side-effect associated with panitumumab was skin rash (77.9% all grades, and 18.6% of grades 3-4).
In conclusion, in the StarPan/STAR-02 Study the primary end point is not reached and the panitumumab combination treatment was associated with high incidence of grade 3-4 diarrhea (with one toxic death). Therefore, this regimen is unsuitable for further testing. The integration of anti-EGFR monoclonal antibodies into rectal cancer preoperative chemoradiation schedules is an interesting and attractive hypothesis, but the interactions between biological therapy and radiochemotherapy could be modified with the different agents applied, treatment schedules, and sequences. The higher pCR obtained in this study in comparison with the previous published phase II studies with an anti-EGFR agent in combination with fluoropyrimidine-oxaliplatin and RT may guide to developing some hypotheses. This result could be correlated to the different modalities of chemotherapy regimen administered. Further translational and clinical studies will be necessary to understand the potential molecular pathways involved in anti-EGFR response, and optimal regimens and sequences with chemo-RT.
The radiosensitizing properties of anti-EGFR in preclinical systems, the results of our study in pathological response and toxicity and the activity of cetuximab in combination with RT alone in head and neck cancers [18] [19] [20] , represent the background of the next STAR Study (Rap Study/STAR-03) that will evaluate panitumumab in combination with only RT in low-risk LARC. 
